prof. Krystyna Dzierzbicka, Ph.D., D.Sc. Eng.


The subject of conducted research concerns the design and synthesis of new chemotherapeutic agents as potential anticancer or immunostimulating drugs, e.g. muramylpeptide and desmuramylpeptide conjugates (fragments of bacterial cell walls), acridine derivatives, acridone, batracillin, anthraquinones, combretastatin, mycophenolic acid and peptides (tuftsin / retro-tuftsin).
Currently conducted research includes the design (using molecular modeling techniques) and synthesis of inhibitors used in neurodegenerative diseases (e.g. Alzheimer's disease) and oligopeptide analogs:

  • carnosine – a dipeptide showing high health-promoting potential and potential application in the treatment of diseases induced by oxidative stress;
  • opioid growth factor (Met-enkephalins) as non-toxic compounds with potential anti-tumor activity.

The specified research is interdisciplinary (synthesis-activity) and is carried out in cooperation with other research centers in the field of biological research.
 

Selected publications:

  1. Budka J., Kowalski S., Chylińska M., Dzierzbicka K., Inkielewicz-Stepniak I.: Opioid growth factor and its derivatives as potential non-toxic multifunctional anticancer and analgesic compounds, Curr. Med. Chem., 2021, 28(4), 673–686.
  2. Cichorek M., Ronowska A., Dzierzbicka K., Gensicka-Kowalewska M., Deptula M., Pelikant-Malecka I.: Chloroacridine derivatives as potential anticancer agents which may act as tricarboxylic acid cycle enzyme inhibitors, Biomedicine Pharmacotherapy, 2020, 130, 110515.
  3. Chmielewska K., Dzierzbicka K., Inkielewicz-Stepniak I., Przybyłowska M.: Therapeutic potential of carnosine and its derivatives in the treatment of human diseases, Chem. Res. Toxicol., 2020, 33(7), 1561–1578.
     

Return to the list of employees